

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Substitute for form 1449A/PTO

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 1 of 2

<b>Application Number</b>	10/523445
<b>Filing Date</b>	01/31/2005
<b>First Named Inventor</b>	Dominique Surleraux
<b>Group Art Unit</b>	1614
<b>Examiner Name</b>	
<b>Attorney Docket Number</b>	TIP-0040USNP

## U.S. PATENT DOCUMENTS

[illegible]

## FOREIGN PATENT DOCUMENTS

Examiner Initials	Cite No. <sup>1</sup>	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document mm-dd-yyyy	Pages, Columns, Lines, where relevant passages or relevant figures appear	T <sup>6</sup>
		Office <sup>3</sup>	Number <sup>4</sup>	KindCode <sup>5</sup>				
/SW/		EP	0445926	B1	Milliken Research Corporation	08-21-1996		
/SW/		EP	0499299	B1	NanoSystems LLC	08-16-2000		
/SW/		EP	0721331	B1	AstraZenecaAB	12-05-2001		
/SW/		WO	94/05263	A1	Janssen Pharmaceutica N.V.	03-17-1994		
/SW/		WO	95/06030	A1	G.D. Searle & Co.	03-02-1995		
/SW/		WO	96/22287	A1	G.D. Searle & Co.	07-25-1996		
/SW/		WO	96/28418	A1	G.D. Searle & Co.	09-19-1996		

Examiner Signature	/Shengjun Wang/	Date Considered	12/19/2008
--------------------	-----------------	-----------------	------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Unique citation designation number. 2 See attached Kinds of U.S. Patent Documents. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS, SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet 2 of 2

Application Number	10/523445
Filing Date	01/31/2005
First Named Inventor	Dominique Surteraux
Group Art Unit	1614
Examiner Name	
Attorney Docket Number	TIP-0040USNP

**FOREIGN PATENT DOCUMENTS**

Examiner Initials	Cite No. <sup>1</sup>	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document mm-dd-yyyy	Pages, Columns, Lines, where relevant passages or relevant figures appear	T <sup>2</sup>
		Office <sup>3</sup>	Number <sup>4</sup>	KindCode <sup>5</sup>				
/SW/		WO	96/28463	A1	G.D. Searle & Co.	09-19-1996		
		WO	96/28464	A1	G.D. Searle & Co.	09-19-1996		
		WO	96/28465	A1	G.D. Searle & Co.	09-19-1996		
		WO	97/18205	A1	G.D. Searle & Co.	05-22-1997		
		WO	97/44014	A1	Janssen Pharmaceutica N.V.	11-27-1997		
		WO	98/42318	A1	Janssen Pharmaceutica N.V.	10-01-1998		
		WO	99/33792	A2	Vertex Pharmaceuticals Incorporated	07-08-1999		
		WO	99/33793	A2	Vertex Pharmaceuticals Incorporated	07-08-1999		
		WO	99/33795	A1	Vertex Pharmaceuticals Incorporated	07-08-1999		
		WO	99/33815	A1	Vertex Pharmaceuticals Incorporated	07-08-1999		
		WO	99/67254	A2	U.S.A., Dept. Of Health & Human Services & Board of Trustees of Univ. of Illinois	12-29-1999		
		WO	99/67417	A2	U.S.A., Dept. Of Health & Human Services	12-29-1999		
/SW/		WO	02/083657	A2	Tibotec Pharmaceuticals, Inc.	10-24-2002		

**OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS**

Examiner's Initials	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T <sup>2</sup>
/SW/		BENET, L. et al., "Pharmacokinetics: The Dynamics of Drug Absorption, Distribution, and Elimination.", <u>Goodman and Gilman's The Pharmacological Basis of Therapeutics</u> , Eighth Edition, pages 13-20, McGraw-Hill Inc.	
/SW/		CROSS, et al., "Rules For The Nomenclature of Organic Chemistry, Section E: Stereochemistry." <u>Pure &amp; Applied Chemistry</u> , 1976, pages 13-30, Vol. 45., Pergamon Press, Great Britain.	
/SW/		HERTOGS, K. et al., "A Rapid Method for Simultaneous Detection of Phenotypic Resistance to Inhibitors of Protease and Reverse Transcriptase in Recombinant Human Immunodeficiency Virus Type 1 Isolates from Patients Treated with Antiretroviral Drugs.", <u>Antimicrobial Agents and Chemotherapy</u> , Feb. 1998, pages 269-276, Vol. 42, No. 2.	
/SW/		PAUWELS et al., "Rapid an Automated Tetrazolium-based Colorimetric Assay for the Detection of Anti-HIV Compounds.", <u>Journal of Virological Methods</u> , 1988, Vol. 20, pages 309-321.	

Examiner Signature	/Shengjun Wang/	Date Considered	/SW/
-----------------------	-----------------	--------------------	------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231.

DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

<p>SUBMISSION UNDER MPEP 609 D</p> <p>Page 1 of</p>	<i>Application Number</i>	10/523
	<i>Filing Date</i>	01/31/2005
	<i>First Named Inventor</i>	Dominique Surteraux
	<i>Group Art Unit</i>	1614
	<i>Examiner Name</i>	
	<i>Attorney Docket Number</i>	TIP-0040USNP

[illegible][illegible][illegible]

Examiner Signature	/Shengjun Wang/	Date Considered	/SW/
-----------------------	-----------------	--------------------	------